Pathology and Laboratory: 4.4× the Insurer's Own Benchmark
In the last quarter of 2025 the median prevailing offer in pathology and laboratory disputes was 4.4× the qualifying payment amount — the figure the plan itself calculated. Across the second half of 2025, certified IDR entities decided 69,871 payment determinations in this category, covering 322,092 items or services.
What the Federal Data Says About Pathology and Laboratory
How to read this. The qualifying payment amount is the plan's own calculated benchmark — generally the median contracted rate for the service in the geographic area. A median prevailing offer of 4.4× QPA means that in half of the decided disputes in this category, the offer the certified IDR entity selected was at least 4.4 times what the plan had calculated. It is a measure of the gap between the plan's benchmark and what an independent entity found defensible. It is not a prediction, a guarantee, or an average recovery for any particular practice, and it does not include disputes that were found ineligible or that closed before a determination. CPT range for this category: 80047–89398 and 0001U–0475U (clinical pathology, anatomic pathology, proprietary laboratory analyses).
Source: CMS, Federal Independent Dispute Resolution Process — Supplemental Tables, Q3 and Q4 2025, Table 14 (prevailing offers relative to QPA by specialty) and Table 12 (payment determination outcomes). Published by CMS here.
Why Pathology and Laboratory Claims End Up Out of Network
Pathology is ancillary under the No Surprises Act, and it is ancillary in the purest sense: the patient has no contact with the pathologist at all. A specimen is taken at an in-network facility and read by whoever the facility's arrangement sends it to. Balance billing is prohibited and consent cannot be obtained.
Pathology claims tend to be individually small, which historically discouraged disputes — the administrative fee could approach or exceed the amount in controversy. That calculation changed materially in 2026, when the administrative fee dropped from $115 to $15 per party per dispute. Combined with batching, small-dollar pathology claims became economically disputable for the first time.
Deciding Whether a Claim Is Worth Disputing
Three things determine whether a specific claim belongs in federal arbitration, and none of them is the specialty itself.
1. Is the claim eligible?
Roughly one in five disputes initiated in 2025 was found ineligible — the single largest source of wasted effort in this process. Eligibility turns on whether the item or service falls under the federal protections rather than a state process, whether open negotiation ran its full 30 business days, and whether the dispute was filed within the four-business-day window that follows. Getting this wrong costs the fee and the claim.
2. Does the arithmetic work?
Since June 11, 2026, the administrative fee is $15 per party per dispute, down from $115. The certified IDR entity fee is set within a range published annually by the Departments and is paid by the non-prevailing party. Against those costs, the relevant question is the gap between the plan's payment and a defensible value for the service — and the federal data shows that gap by claim size is largest on smaller claims, not larger ones.
3. Can the claims be batched?
Qualifying claims may be submitted together in a single dispute. For a pathology and laboratory practice generating similar claims against the same plan, batching is usually what turns a marginal economic case into a clear one.
We review claims against these three tests before anything is filed, and we are paid only out of what is actually recovered. If the claims do not clear the tests, we say so.